恩替卡韦和替诺福韦对初治代偿期乙肝肝硬化疗效比较

Comparison of the efficacy of entecavir and tenofovir in the treatment of patients with chronic hepatitis B and compensatory cirrhosis

目的 :研究恩替卡韦(ETV)和替诺福韦(TDF)对初治乙肝肝硬化的治疗效果。方法 :选取本院诊断代偿期乙肝肝硬化患者60例随机分为对照组(予以ETV治疗)和观察组(予以TDF治疗)各30例,观察疗效共48周。结果:对照组和观察组患者的基线特征差异(P均> 0.05)及观察结束时HBV DNA <100 IU/ml发生率差异(P=0.612)均无统计学意义;观察组ALT正常率高于对照组(P=0.045)、Child-Pugh评分低于对照组低(P=0.037)。结论 :TDF较ETV有更高的改善肝功能及Child-Pugh评分的作用。

Objective:To study the efficacy of entecavir and tenofovir in the treatment of patients with chronic hepatitis B and compensatory cirrhosis.Methods:Sixty compensatory cirrhosis patients with chronic hepatitis B were randomly divided into a control group(treated with entecavir)and an observation group(treated with tenofovir)with 30 cases each and their efficacy was observed till 48 weeks.Results:The comparison of baseline characteristics(P>0.05)and the incidence of HBV DNA<100 IU/ml at the end of the observation(P=0.612)between the two groups showed no statistical significance.The normal rate of ALT was higher(P=0.045)while the Child-Pugh score was lower(P=0.037)in the observation group than the control group.Conclusion:The efficacy of tenofovir was better than that of entecavir in the improvement of liver function and Child-Pugh score.